Lipum (publ) recruited Dr. Fredrik Seijsing to strengthen the preclinical development of SOL-116. Dr. Seijsing has a PhD in Molecular Bioscience from Wenner-Gren's institute at Stockholm University and a master's degree in Medicinal biotechnology from Umeå University. He also has industry experience as process engineer from Cobra Biologics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.9 SEK | 0.00% |
|
+6.59% | +36.50% |
Jun. 18 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
May. 28 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.50% | 17.84M | |
+7.40% | 101B | |
+8.42% | 42.18B | |
-13.43% | 32.26B | |
+80.80% | 29.79B | |
-11.42% | 16.06B | |
+1.92% | 14.45B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
+4.12% | 8.89B |
- Stock Market
- Equities
- LIPUM Stock
- News Lipum AB
- Lipum Recruits Fredrik Seijsing as Scientist